501. The tick salivary protein sialostatin L inhibits the Th9-derived production of the asthma-promoting cytokine IL-9 and is effective in the prevention of experimental asthma.
- Author
-
Horka H, Staudt V, Klein M, Taube C, Reuter S, Dehzad N, Andersen JF, Kopecky J, Schild H, Kotsyfakis M, Hoffmann M, Gerlitzki B, Stassen M, Bopp T, and Schmitt E
- Subjects
- Animals, Asthma metabolism, Asthma prevention & control, Cell Separation, Cystatins pharmacology, Cytokines immunology, Cytokines metabolism, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Interleukin-9 biosynthesis, Male, Mice, Mice, Inbred BALB C, Mice, Knockout, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocyte Subsets metabolism, Asthma immunology, Cystatins immunology, Interleukin-9 immunology, Ixodidae immunology, T-Lymphocyte Subsets immunology
- Abstract
Ticks developed a multitude of different immune evasion strategies to obtain a blood meal. Sialostatin L is an immunosuppressive cysteine protease inhibitor present in the saliva of the hard tick Ixodes scapularis. In this study, we demonstrate that sialostatin L strongly inhibits the production of IL-9 by Th9 cells. Because we could show recently that Th9-derived IL-9 is essentially involved in the induction of asthma symptoms, sialostatin L was used for the treatment of experimental asthma. Application of sialostatin L in a model of experimental asthma almost completely abrogated airway hyperresponsiveness and eosinophilia. Our data suggest that sialostatin L can prevent experimental asthma, most likely by inhibiting the IL-9 production of Th9 cells. Thus, alternative to IL-9 neutralization sialostatin L provides the basis for the development of innovative therapeutic strategies to treat asthma.
- Published
- 2012
- Full Text
- View/download PDF